Qiagen NV 

(Public, NASDAQ:QGEN)   Watch this stock   
Find more results for QGEN
May 4, 2010
Q1 2010 Earnings Conference Call - 9:30AM EDT - Add to calendar
May 2, 2010
Q1 2010 Earnings Release Add to calendar
Feb 11, 2010
Analyst and Investor Day - 1:00PM EST - Add to calendar
Feb 9, 2010
Q4 & Full Year 2009 Earnings & Guidance Conference Call
Feb 7, 2010
Q4 & Full Year 2009 Earnings & Guidance Release
Jan 13, 2010
JPMorgan Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 14.52% 10.03%
Operating margin 20.55% 16.31%
EBITD margin - 28.14%
Return on average assets 4.50% 3.16%
Return on average equity 8.03% 6.26%
Employees 3,041 -

Address

Spoorstraat 50
Venlo, 5911 KJ
Netherlands
+31-77-3208400 (Phone)
+31-77-3208409 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Discussion Group - Google Finance

Qiagen NV discussed on blogs

College & University Related News: PRN: QIAGEN Acquires Exclusive ... - jon - College & University Related News - Feb 8, 2010
theback9: Event Calander Feb 8-13 - theback 9 - theback9 - Feb 8, 2010

Description

QIAGEN N.V. (QIAGEN) is a provider of technologies and products for preanalytical sample preparation and linked molecular assay solutions. The Company has developed a portfolio of more than 500 consumable products and automated solutions for sample collection, and nucleic acid and protein handling, separation, and purification, as well as open and target specific assays. The Company also supplies diagnostic kits, tests, and assays for human and veterinary molecular diagnostics. Products are sold to academic research markets, to pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications), as well as to molecular diagnostics laboratories. In addition, the Company sells and/or licenses technologies to others. The Company’s products are markets in more than 40 countries. In January 2010, the Company announced that it has acquired ESE GmbH.

Officers and directors

Detlev H. Riesner Ph.D.
Chairman of the Supervisory Board
Age: 66
Bio & Compensation - Reuters
Peer M. Schatz
Chief Executive Officer, Managing Director
Age: 42
Bio & Compensation - Reuters
Erik Hornnaess
Deputy Chairman of the Supervisory Board
Age: 70
Bio & Compensation - Reuters
Roland Sackers
Chief Financial Officer, Managing Director
Portrait. Age: 39
Bio & Compensation - Reuters
Bernd Uder
Senior Vice President Global Sales, Managing Director
Portrait. Age: 50
Bio & Compensation - Reuters
Joachim Schorr
Senior Vice President - Research and Development, Managing Director
Portrait. Age: 47
Bio & Compensation - Reuters
Douglas Liu
Vice President, Global Operations
Bio & Compensation - Reuters
Thomas Schweins
Vice President, Marketing and Strategy
Bio & Compensation - Reuters
Michael Collasius
Vice President - Automated Systems
Bio & Compensation - Reuters
Ulrich Schriek
Vice President, Corporate Business Development
Bio & Compensation - Reuters